Protocol Ledger

NCT07296484 · Phase II · RECRUITING

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

Interventional Phase II clinical trial protocol NCT07296484 sponsored by Sparrow Pharmaceuticals in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-11-29 Enrollment: 1,500 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07296484
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,500 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07296484
Protocol FieldVerified Registry Value
NCT IdentifierNCT07296484
Consolidated Lead SponsorSparrow Pharmaceuticals
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment1,500 participants (ESTIMATED)
Registered Start Date2025-11-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07296484
Hospital Research SiteLocationSite Profile
Velocity Clinical Research (Huntington Park)Huntington Park, CAOpen Hospital Dossier ->
Velocity Clinical Research (La Mesa)La Mesa, CAOpen Hospital Dossier ->
Velocity Clinical Research (Los Angeles)Los Angeles, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI